Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase II study.

BMC Pulm Med · 2024 · PMC11462669 · PMID 39379903

Europe PMC DOI

hedged sentence

0.1350

closest p · 2.7× alpha

0.1350

boldest claim

The sentences

showed a trendp = 0.135not close (p > 0.1)

Patients with irP relapse showed a trend toward a longer duration from the start of ICI administration to the onset of irP than those without irP relapse ( p = 0.135).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.